Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity.

PubWeight™: 1.61‹?› | Rank: Top 4%

🔗 View Article (PMID 16837598)

Published in J Neurosci on July 12, 2006

Authors

Yan Leng1, De-Maw Chuang

Author Affiliations

1: Molecular Neurobiology Section, Biological Psychiatry Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892-1363, USA.

Articles citing this

Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci (2009) 2.95

Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann N Y Acad Sci (2008) 1.94

Phase II open label study of valproic acid in spinal muscular atrophy. PLoS One (2009) 1.67

Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci (2008) 1.58

SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy. PLoS One (2010) 1.45

Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience (2007) 1.42

Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression. Synapse (2007) 1.41

Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int J Neuropsychopharmacol (2008) 1.38

GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci Biobehav Rev (2007) 1.36

Valproic acid induces functional heat-shock protein 70 via Class I histone deacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation. J Neurochem (2009) 1.28

SMA CARNIVAL TRIAL PART II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy. PLoS One (2011) 1.19

Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism. Am J Pathol (2011) 1.17

α-Synuclein negatively regulates protein kinase Cδ expression to suppress apoptosis in dopaminergic neurons by reducing p300 histone acetyltransferase activity. J Neurosci (2011) 1.16

The mood stabilizers valproic acid and lithium enhance mesenchymal stem cell migration via distinct mechanisms. Neuropsychopharmacology (2010) 1.07

Selective binding of nuclear alpha-synuclein to the PGC1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: implications for Parkinson's disease. Free Radic Biol Med (2012) 1.04

Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy. Exp Neurol (2012) 1.01

Post-insult valproic acid-regulated microRNAs: potential targets for cerebral ischemia. Am J Transl Res (2012) 0.99

α-Synuclein controls mitochondrial calcium homeostasis by enhancing endoplasmic reticulum-mitochondria interactions. J Biol Chem (2012) 0.98

Peroxidase mechanism of lipid-dependent cross-linking of synuclein with cytochrome C: protection against apoptosis versus delayed oxidative stress in Parkinson disease. J Biol Chem (2009) 0.94

Epigenetic mechanisms in cerebral ischemia. J Cereb Blood Flow Metab (2013) 0.93

Beneficial effects of mood stabilizers lithium, valproate and lamotrigine in experimental stroke models. Acta Pharmacol Sin (2011) 0.93

Mood stabilizer-regulated miRNAs in neuropsychiatric and neurodegenerative diseases: identifying associations and functions. Am J Transl Res (2013) 0.92

Histone deacetylase inhibition alters histone methylation associated with heat shock protein 70 promoter modifications in astrocytes and neurons. Neuropharmacology (2010) 0.92

α-Synuclein and neuronal cell death. Mol Neurobiol (2012) 0.92

Novel one-step immunoassays to quantify α-synuclein: applications for biomarker development and high-throughput screening. J Biol Chem (2012) 0.90

Unique functional roles for class I and class II histone deacetylases in central nervous system development and function. Int J Dev Neurosci (2013) 0.90

Therapeutic neuroprotective agents for amyotrophic lateral sclerosis. Cell Mol Life Sci (2013) 0.88

SMA valiant trial: a prospective, double-blind, placebo-controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle Nerve (2014) 0.88

Valproic acid: an anticonvulsant drug with potent antinociceptive and anti-inflammatory properties. Naunyn Schmiedebergs Arch Pharmacol (2013) 0.87

Histone deacetylases and mood disorders: epigenetic programming in gene-environment interactions. CNS Neurosci Ther (2010) 0.87

Telmisartan ameliorates glutamate-induced neurotoxicity: roles of AT(1) receptor blockade and PPARγ activation. Neuropharmacology (2013) 0.86

FGF-21, a novel metabolic regulator, has a robust neuroprotective role and is markedly elevated in neurons by mood stabilizers. Mol Psychiatry (2014) 0.85

Aspects of innate immunity and Parkinson's disease. Front Pharmacol (2012) 0.85

Antagonizing Neuronal Toll-like Receptor 2 Prevents Synucleinopathy by Activating Autophagy. Cell Rep (2015) 0.85

Potent neuroprotective effects of novel structural derivatives of valproic acid: potential roles of HDAC inhibition and HSP70 induction. Neurosci Lett (2010) 0.84

α-Synuclein overexpression represses 14-3-3θ transcription. J Mol Neurosci (2013) 0.81

Alpha-synuclein loss in spinal muscular atrophy. J Mol Neurosci (2010) 0.81

Considerations on the role of environmental toxins in idiopathic Parkinson's disease pathophysiology. Transl Neurodegener (2014) 0.80

Epigenetics-Based Therapeutics for Neurodegenerative Disorders. Curr Transl Geriatr Exp Gerontol Rep (2012) 0.80

The Smn-independent beneficial effects of trichostatin A on an intermediate mouse model of spinal muscular atrophy. PLoS One (2014) 0.79

Potential molecular and cellular mechanism of psychotropic drugs. Clin Psychopharmacol Neurosci (2014) 0.79

A novel GSK-3β inhibitor YQ138 prevents neuronal injury induced by glutamate and brain ischemia through activation of the Nrf2 signaling pathway. Acta Pharmacol Sin (2016) 0.78

Emerging roles of epigenetic mechanisms in Parkinson's disease. Funct Integr Genomics (2011) 0.78

3',4'-Dimethoxyflavone and valproic acid promotes the proliferation of human hematopoietic stem cells. Stem Cell Res Ther (2013) 0.78

Valproic Acid Regulates α-Synuclein Expression through JNK Pathway in Rat Primary Astrocytes. Biomol Ther (Seoul) (2013) 0.78

Nanomolar concentration of alpha-synuclein enhances dopaminergic neuronal survival via Akt pathway. Neural Regen Res (2013) 0.78

Phenylbutyrate-a pan-HDAC inhibitor-suppresses proliferation of glioblastoma LN-229 cell line. Tumour Biol (2015) 0.78

Valproic acid enhances the efficacy of radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells. Oncotarget (2015) 0.78

The neuroprotective disease-modifying potential of psychotropics in Parkinson's disease. Parkinsons Dis (2011) 0.77

Generation of SNCA Cell Models Using Zinc Finger Nuclease (ZFN) Technology for Efficient High-Throughput Drug Screening. PLoS One (2015) 0.77

Aged monkey brains reveal the role of ubiquitin-conjugating enzyme UBE2N in the synaptosomal accumulation of mutant huntingtin. Hum Mol Genet (2014) 0.77

Valproic Acid and Other HDAC Inhibitors Upregulate FGF21 Gene Expression and Promote Process Elongation in Glia by Inhibiting HDAC2 and 3. Int J Neuropsychopharmacol (2016) 0.76

Modulation of synaptic transmission and analysis of neuroprotective effects of valproic Acid and derivates in rat embryonic motoneurons. Cell Mol Neurobiol (2010) 0.76

The role of quercetin on the survival of neuron-like PC12 cells and the expression of α-synuclein. Neural Regen Res (2015) 0.76

Transcriptional Regulation of the Astrocytic Excitatory Amino Acid Transporter 1 (EAAT1) via NF-κB and Yin Yang 1 (YY1). J Biol Chem (2015) 0.76

Aberrant histone acetylation promotes mitochondrial respiratory suppression in the brain of alcoholic rats. J Pharmacol Exp Ther (2014) 0.76

Current Therapy of Drugs in Amyotrophic Lateral Sclerosis. Curr Neuropharmacol (2016) 0.75

Valproic Acid Protects Primary Dopamine Neurons from MPP(+)-Induced Neurotoxicity: Involvement of GSK3β Phosphorylation by Akt and ERK through the Mitochondrial Intrinsic Apoptotic Pathway. Biomed Res Int (2017) 0.75

Histone H3 acetylation in the postmortem Parkinson's disease primary motor cortex. Neurosci Lett (2016) 0.75

A new glucocerebrosidase-deficient neuronal cell model provides a tool to probe pathophysiology and therapeutics for Gaucher disease. Dis Model Mech (2016) 0.75

Common key-signals in learning and neurodegeneration: focus on excito-amino acids, beta-amyloid peptides and alpha-synuclein. J Neural Transm (Vienna) (2008) 0.75

The Role of Presenilin-1 in the Excitotoxicity of Ethanol Withdrawal. J Pharmacol Exp Ther (2016) 0.75

Articles by these authors

Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther (2007) 2.90

Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J Neurochem (2004) 2.21

Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease. Neuropsychopharmacology (2011) 1.66

Postinsult treatment with lithium reduces brain damage and facilitates neurological recovery in a rat ischemia/reperfusion model. Proc Natl Acad Sci U S A (2003) 1.62

Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci (2008) 1.58

Differential roles of glycogen synthase kinase-3 isoforms in the regulation of transcriptional activation. J Biol Chem (2006) 1.57

PET imaging with [11C]PBR28 can localize and quantify upregulated peripheral benzodiazepine receptors associated with cerebral ischemia in rat. Neurosci Lett (2006) 1.56

Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem (2002) 1.55

Valproic acid attenuates blood-brain barrier disruption in a rat model of transient focal cerebral ischemia: the roles of HDAC and MMP-9 inhibition. J Cereb Blood Flow Metab (2010) 1.53

The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brain. J Neurochem (2009) 1.53

Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev (2013) 1.52

Regulation and function of glycogen synthase kinase-3 isoforms in neuronal survival. J Biol Chem (2006) 1.48

Lithium neuroprotection: molecular mechanisms and clinical implications. Expert Rev Mol Med (2004) 1.44

Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol Ther (2010) 1.39

Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int J Neuropsychopharmacol (2008) 1.38

GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci Biobehav Rev (2007) 1.36

Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity. Neuropharmacology (2002) 1.34

Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome. Int J Neuropsychopharmacol (2010) 1.31

Valproic acid induces functional heat-shock protein 70 via Class I histone deacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation. J Neurochem (2009) 1.28

Angiotensin II AT1 receptor blockade ameliorates brain inflammation. Neuropsychopharmacology (2010) 1.21

Valproic acid, a mood stabilizer and anticonvulsant, protects rat cerebral cortical neurons from spontaneous cell death: a role of histone deacetylase inhibition. FEBS Lett (2003) 1.18

Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia. Brain Res Mol Brain Res (2004) 1.18

The mood stabilizers valproic acid and lithium enhance mesenchymal stem cell migration via distinct mechanisms. Neuropsychopharmacology (2010) 1.07

Mesenchymal stem cells primed with valproate and lithium robustly migrate to infarcted regions and facilitate recovery in a stroke model. Stroke (2011) 1.06

Chronic valproate treatment enhances postischemic angiogenesis and promotes functional recovery in a rat model of ischemic stroke. Stroke (2012) 1.01

Regulation of c-Jun N-terminal kinase, p38 kinase and AP-1 DNA binding in cultured brain neurons: roles in glutamate excitotoxicity and lithium neuroprotection. J Neurochem (2003) 1.01

Post-insult valproic acid-regulated microRNAs: potential targets for cerebral ischemia. Am J Transl Res (2012) 0.99

Lithium ameliorates neurodegeneration, suppresses neuroinflammation, and improves behavioral performance in a mouse model of traumatic brain injury. J Neurotrauma (2011) 0.99

Lentivirally mediated GSK-3β silencing in the hippocampal dentate gyrus induces antidepressant-like effects in stressed mice. Int J Neuropsychopharmacol (2010) 0.98

Lithium inhibits Smad3/4 transactivation via increased CREB activity induced by enhanced PKA and AKT signaling. Mol Cell Neurosci (2007) 0.98

Potential roles of HDAC inhibitors in mitigating ischemia-induced brain damage and facilitating endogenous regeneration and recovery. Curr Pharm Des (2013) 0.97

Overexpression and nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase in a transgenic mouse model of Huntington's disease. Mol Cell Neurosci (2003) 0.97

Functional MRI of delayed chronic lithium treatment in rat focal cerebral ischemia. Stroke (2008) 0.96

Beneficial effects of mood stabilizers lithium, valproate and lamotrigine in experimental stroke models. Acta Pharmacol Sin (2011) 0.93

Mood stabilizer-regulated miRNAs in neuropsychiatric and neurodegenerative diseases: identifying associations and functions. Am J Transl Res (2013) 0.92

Histone deacetylase inhibition alters histone methylation associated with heat shock protein 70 promoter modifications in astrocytes and neurons. Neuropharmacology (2010) 0.92

Lithium reduces ischemia-induced hippocampal CA1 damage and behavioral deficits in gerbils. Brain Res (2007) 0.92

Lithium upregulates vascular endothelial growth factor in brain endothelial cells and astrocytes. Stroke (2008) 0.91

Lithium reduces BACE1 overexpression, β amyloid accumulation, and spatial learning deficits in mice with traumatic brain injury. J Neurotrauma (2012) 0.90

Valproic acid attenuates microgliosis in injured spinal cord and purinergic P2X4 receptor expression in activated microglia. J Neurosci Res (2013) 0.89

Bax inhibitor 1, a modulator of calcium homeostasis, confers affective resilience. Brain Res (2011) 0.88

Lithium-induced inhibition of Src tyrosine kinase in rat cerebral cortical neurons: a role in neuroprotection against N-methyl-D-aspartate receptor-mediated excitotoxicity. FEBS Lett (2003) 0.87

Posttrauma cotreatment with lithium and valproate: reduction of lesion volume, attenuation of blood-brain barrier disruption, and improvement in motor coordination in mice with traumatic brain injury. J Neurosurg (2013) 0.87

Neuroprotective action of lithium in disorders of the central nervous system. Zhong Nan Da Xue Xue Bao Yi Xue Ban (2011) 0.87

Potent neuroprotective effects of novel structural derivatives of valproic acid: potential roles of HDAC inhibition and HSP70 induction. Neurosci Lett (2010) 0.84

Susceptibility of striatal neurons to excitotoxic injury correlates with basal levels of Bcl-2 and the induction of P53 and c-Myc immunoreactivity. Neurobiol Dis (2005) 0.83

Nuclear factor-kappaB-dependent cyclin D1 induction and DNA replication associated with N-methyl-D-aspartate receptor-mediated apoptosis in rat striatum. J Neurosci Res (2007) 0.79

[Neuroprotective actions of lithium]. Seishin Shinkeigaku Zasshi (2003) 0.79

Neuroprotective effects of the mood stabilizer lamotrigine against glutamate excitotoxicity: roles of chromatin remodelling and Bcl-2 induction. Int J Neuropsychopharmacol (2012) 0.77